Ipsen has posted drug sales of EUR258m, an increase of 6.3%, compared to EUR242.8m for the year ago period. This performance was driven by strong specialty care sales, with all products growing double digit: oncology, endocrinology and neurology grew 11.4, 23.3 and 16% excluding foreign exchange impacts respectively over the period.
Specialty care sales reached EUR168.5m, up 17.1% year-on-year, and its relative weight in total drug sales grew to 65.3% from 59.3% a year earlier. Primary Care sales reached EUR89.5m, down 9.5% year-on-year, impacted by slower sales in France notably.
Jean-Luc Belingard, chairman and CEO of Ipsen, said: “Ipsen’s specialty care franchise is more than ever confirming its high growth potential and has passed a landmark, as it now represents nearly two thirds of Ipsen’s total drug sales.
“In the near future, capitalising on these positive developments, Ipsen will continue to progress its rich R&D pipeline, optimise the contribution of its presence in primary care and strengthen its R&D organisation.”